Loteprednol
From Wikipedia, the free encyclopedia
Loteprednol etabonate
|
|
Systematic (IUPAC) name | |
chloromethyl 17-ethoxycarbonyloxy- 11-hydroxy- 10,13-dimethyl-3-oxo- 7,8,9,11,12,14,15, 16-octahydro- 6H-cyclopenta[a] phenanthrene-17-carboxylate | |
Identifiers | |
CAS number | |
ATC code | S01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C24H31ClO7 |
Mol. mass | 466.951 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
C(US) |
Legal status | |
Routes | ? |
Loteprednol (as the ester loteprednol etabonate) is a corticosteroid used in ophthalmology.
In the US, it is marketed by Bausch and Lomb as Lotemax.
Ocular applications for this drug include the treatment of chronic adenoviral keratitis, Thygeson’s keratitis, vernal keratoconjunctivitis, pingueculitis, and episcleritis. Its use has little or no effect on IOP